Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The study concluded that dutasteride 0.5 mg daily for 24 weeks was the most effective monotherapy for increasing hair density in men with androgenetic alopecia, compared to other interventions.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

The research concluded that in men with androgenetic alopecia, dutasteride was more effective than finasteride at increasing hair count after 24 weeks, with similar side effect profiles.

This review of female androgenetic alopecia treatments reports limited therapeutic options due to unclear pathogenesis, with minoxidil as the only FDA-approved treatment and adjuvant therapies under investigation.

This meta-analysis concluded that 5α-reductase inhibitors may increase the risk of mild depression, particularly with dutasteride, in patients treated for benign prostatic hyperplasia and androgenic alopecia.

Dutasteride is more effective than finasteride for hair growth with similar side effects.

In this review and meta-analysis, the authors concluded that 5α-reductase inhibitor therapy is not consistently associated with significant increases in serum testosterone levels in men.

This guideline review by the European Dermatology Forum evaluates current treatments for androgenetic alopecia but reports no new research findings, aiming to assist dermatologists in selecting safe and effective therapies.

This article discusses the FDA's decision not to approve 5α-reductase inhibitors for prostate cancer prevention, citing an increase in high-grade tumors but no mortality evidence, and reports no new results.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

This study reviewed human evidence on the effects of 5α-reductase inhibitors, finasteride and dutasteride, on semen parameters and gonadotrophins, finding finasteride causes mild, reversible changes, while dutasteride may lead to more pronounced and potentially less reversible impacts, suggesting caution for those planning to conceive.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.

This review analyzed the use of 5-alpha reductase inhibitors (5ARIs) for treating various dermatological conditions such as androgenetic alopecia, acne, and hirsutism, emphasizing their efficacy and safety profile.

This review provides an in-depth examination of the efficacy and safety of finasteride and dutasteride, commonly used for treating benign prostatic hyperplasia and male androgenetic alopecia.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.